Compare Stocks

→ Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNAB Social Capital Suvretta Holdings Corp. II	$10.35 +0.1%	$10.33	$9.70 ▼ $11.02	$330.06M	0.02	120,368 shs	142,500 shs
FHLT Future Health ESG	$12.30 +4.7%	$11.23	$9.97 ▼ $15.05	$73.06M	-0.05	7,376 shs	5,965 shs
IBER Ibere Pharmaceuticals	$10.18	$10.17	$9.74 ▼ $10.75	$175.61M	N/A	110,000 shs	44,499 shs
NAMS NewAmsterdam Pharma	$21.99 +2.6%	$21.61	$5.63 ▼ $26.35	$1.96B	0.02	236,708 shs	62,741 shs

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNAB Social Capital Suvretta Holdings Corp. II	0.00%	0.00%	0.00%	0.00%	+0.78%
FHLT Future Health ESG	+1.91%	-7.48%	+9.00%	+9.51%	+15.76%
IBER Ibere Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
NAMS NewAmsterdam Pharma	-1.65%	+10.29%	-5.63%	-3.86%	+53.14%

Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNAB Social Capital Suvretta Holdings Corp. II	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FHLT Future Health ESG	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IBER Ibere Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	3.2474 of 5 stars	3.5	4.0	0.0	0.0	2.5	3.3	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNAB Social Capital Suvretta Holdings Corp. II	N/A	N/A	N/A	N/A
FHLT Future Health ESG	N/A	N/A	N/A	N/A
IBER Ibere Pharmaceuticals	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	3.00	Buy	$33.25	51.21% Upside

Current Analyst Ratings

Latest NAMS, FHLT, IBER, and DNAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/14/2024	NAMS NewAmsterdam Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform ➝ Sector Outperform	$35.00
2/29/2024	NAMS NewAmsterdam Pharma	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$25.00 ➝ $31.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNAB Social Capital Suvretta Holdings Corp. II	N/A	N/A	$0.09 per share	120.33	($0.23) per share	N/A
FHLT Future Health ESG	N/A	N/A	N/A	N/A	($1.56) per share	N/A
IBER Ibere Pharmaceuticals	N/A	N/A	$0.09 per share	112.42	($0.63) per share	N/A
NAMS NewAmsterdam Pharma	$14.09M	139.32	N/A	N/A	$3.50 per share	6.28

Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNAB Social Capital Suvretta Holdings Corp. II	$2.74M	N/A	∞	N/A	N/A	-73.34%	2.13%	N/A
FHLT Future Health ESG	-$50K	N/A	∞	N/A	N/A	-9.79%	-0.28%	N/A
IBER Ibere Pharmaceuticals	$1.56M	N/A	∞	N/A	N/A	-83.01%	4.47%	N/A
NAMS NewAmsterdam Pharma	-$176.94M	N/A	N/A	N/A	N/A	N/A	N/A	5/22/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNAB Social Capital Suvretta Holdings Corp. II	N/A	N/A	N/A	N/A	N/A
FHLT Future Health ESG	N/A	N/A	N/A	N/A	N/A
IBER Ibere Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNAB Social Capital Suvretta Holdings Corp. II	N/A	0.98	0.98
FHLT Future Health ESG	N/A	0.02	0.02
IBER Ibere Pharmaceuticals	N/A	0.24	0.24
NAMS NewAmsterdam Pharma	N/A	6.95	6.95

Ownership

Institutional Ownership

Company	Institutional Ownership
DNAB Social Capital Suvretta Holdings Corp. II	76.58%
FHLT Future Health ESG	24.57%
IBER Ibere Pharmaceuticals	69.66%
NAMS NewAmsterdam Pharma	89.89%

Insider Ownership

Company	Insider Ownership
DNAB Social Capital Suvretta Holdings Corp. II	N/A
FHLT Future Health ESG	57.20%
IBER Ibere Pharmaceuticals	20.00%
NAMS NewAmsterdam Pharma	2.50%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
DNAB Social Capital Suvretta Holdings Corp. II	4	31.89 million	N/A	Not Optionable
FHLT Future Health ESG	2,021	5.94 million	2.54 million	Not Optionable
IBER Ibere Pharmaceuticals	3	17.25 million	13.80 million	Not Optionable
NAMS NewAmsterdam Pharma	29	89.27 million	87.04 million	Not Optionable

NAMS, FHLT, IBER, and DNAB Headlines

Source	Headline
	NewAmsterdam Pharma (NASDAQ:NAMS) Trading 6.7% Higher marketbeat.com - April 23 at 1:27 PM
	NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Up to $20.05 americanbankingnews.com - April 20 at 4:42 AM
	NewAmsterdam Pharma (NASDAQ:NAMS) Shares Up 2.6% marketbeat.com - April 16 at 1:40 PM
	NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 2.1% marketbeat.com - April 10 at 2:51 PM
	Amring officially changes name to Nordic Pharma drugstorenews.com - April 9 at 12:34 PM
	BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors businesswire.com - April 9 at 8:00 AM
	NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease globenewswire.com - April 9 at 8:00 AM
	NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 4.9% marketbeat.com - April 8 at 11:59 AM
	Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV) and NewAmsterdam Pharma Company (NAMS) markets.businessinsider.com - April 2 at 8:25 PM
	NewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading Volume marketbeat.com - April 1 at 2:01 PM
	NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer globenewswire.com - April 1 at 8:00 AM
	NewAmsterdam Pharma (NASDAQ:NAMS) Director Acquires $181,223.50 in Stock insidertrades.com - March 29 at 8:42 AM
	NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells $4,095,234.00 in Stock insidertrades.com - March 29 at 5:04 AM
	If you loved NBC's ER, this new Max medical drama is the show for you msn.com - March 28 at 8:17 PM
	NewAmsterdam Pharma (NASDAQ:NAMS) Director Buys $181,223.50 in Stock marketbeat.com - March 28 at 7:31 PM
	Johannes Jacob Piete Kastelein Sells 190,476 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock marketbeat.com - March 27 at 6:39 PM
	NewAmsterdam Pharma (NASDAQ:NAMS) Sees Strong Trading Volume marketbeat.com - March 26 at 12:36 PM
	NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress globenewswire.com - March 25 at 8:00 AM
	NAMS NewAmsterdam Pharma Company N.V. seekingalpha.com - March 19 at 10:02 PM
	NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up zacks.com - March 13 at 2:36 PM
	Amring Pharmaceuticals Rebrands as Nordic Pharma, Eyes Global Expansion with Strategic Acquisition msn.com - March 13 at 8:55 AM
	NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD globenewswire.com - March 12 at 8:00 AM
	NewAmsterdam Pharma Full Year 2023 Earnings: Revenues Miss Expectations finance.yahoo.com - March 1 at 9:45 AM
	NewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update finanznachrichten.de - February 28 at 11:24 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
3 Stocks Leading the U.S. Agriculture Comeback
April 26, 2024 10:10 AM
View 3 Stocks Leading the U.S. Agriculture Comeback
Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 months
April 26, 2024 3:21 AM
View Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 months
How to Use Put Debit Spreads to Profit From Falling Stocks
April 26, 2024 9:30 AM
View How to Use Put Debit Spreads to Profit From Falling Stocks
Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
April 25, 2024 10:36 AM
View Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices

All Headlines

Company Descriptions

Social Capital Suvretta Holdings Corp. II

NASDAQ:DNAB

Social Capital Suvretta Holdings Corp. II does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in biotechnology industry. Social Capital Suvretta Holdings Corp. II was incorporated in 2021 and is based in Henderson, Nevada.

Future Health ESG

NASDAQ:FHLT

Future Health ESG Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to pursue an initial business combination opportunity in the smart health technology sector. Future Health ESG Corp. was incorporated in 2021 and is based in Dover, Delaware.

Ibere Pharmaceuticals

NYSE:IBER

Ibere Pharmaceuticals does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Philadelphia, Pennsylvania.

NewAmsterdam Pharma

NASDAQ:NAMS

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial